GoKawiil
Tech News
New research shows that people taking GLP-1 weight-loss medications like Ozempic are cutting back on spending for certain foods, while increasing spending on fitness, supplements, and clothing. The study points to broader shifts in consumer habits tied to widespread use of these drugs, which can cost users hundreds of dollars monthly.
A new Priceline report finds that Americans taking GLP-1 medications like Ozempic are driving new expectations for hotels, including in-room refrigerators to store medication and menus with higher protein content. The report frames this as part of a broader shift in travel preferences tied to the growing use of weight-loss and diabetes drugs.
New data from Novo Nordisk and Eli Lilly indicates that GLP-1 medications, the class that includes Ozempic, may slow biological aging as measured by molecular aging clocks. These clocks track chemical changes in cells believed to correlate with the pace of aging.
McDonald's is developing new menu options including grilled chicken, wraps and egg bites, alongside smaller portion sizes. The company points to roughly 30 million Americans now using GLP-1 weight-loss drugs as a factor shaping demand for its food offerings.
Novo Nordisk, the Danish pharmaceutical company known for Ozempic and Wegovy, is rebranding itself as simply 'Novo' starting this week. The move shifts the company's public identity toward a shorter, more casual name as it markets directly to consumers rather than solely to healthcare providers.
Researchers at the University of Pennsylvania used AI to analyze over 400,000 Reddit posts from nearly 70,000 users discussing GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound. The analysis, published in Nature Health, surfaced patient-reported symptoms—particularly menstrual changes and temperature issues like chills and hot flashes—that appear underrepresented in clinical trials and regulatory data. The team stresses this doesn't prove the drugs cause these effects, but flags them as signals worth further study.
The Guardian gathered reader accounts describing how GLP-1 drugs like Wegovy, Ozempic and Mounjaro have reshaped family dynamics, with many users hiding their use out of shame. Several described feeling they had 'cheated' at weight loss, straining relationships with partners, children and friends who didn't know about the medication.
New research points to GLP-1 medications, including Ozempic, being associated with fewer or less severe cases of certain infections, among them tuberculosis. Two separate studies form the basis of these findings, suggesting a potential secondary health benefit beyond the drugs' established use in diabetes and weight management.